ProQR Therapeutics Creating RNA therapies for patients in need
On a mission
At ProQR, we are passionate about pushing the boundaries of science and technology to create innovative solutions for unmet medical needs. Our team is dedicated to conducting cutting-edge research and development in the RNA editing field to improve the lives of patients and families affected by genetic disorders.
We believe that every person deserves access to the best possible care, and we are committed to working together as a community to make that happen. Join us on our mission to make a real difference in the lives of those we serve.
Our science
Internal link Working at ProQRLatest press releases
-
Internal link ProQR Announces First Quarter 2024 Operating and Financial Results
-
Internal link ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
-
Internal link ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
ProQR Community News
-
ProQR welcomes a new generation of scientists
Community news -
Catching up with returning ProQRian René Beukema
Community news -
Exploring why companies partner their technology
Community news
ProQR & Eli Lilly and Company partnership
Since 2021 ProQR has partnered with Eli Lilly and Company focusing on the discovery, development, and commercialization of potential new using ProQR’s proprietary Axiomer® RNA editing platform.
Internal link Read about our partnership